Ftse Mib
34.731,31
0,60%
DAX
20.399,16
0,25%
S&P 500
6.084,19
0,82%
NASDAQ
20.034,89
1,77%
Bitcoin
100.956,47
-0,23%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Neoleukin Therapeutics Inc (NLTX) Neoleukin Therapeutics Inc (NLTX) Notizie

NLTX

Neoleukin Therapeutics (NLTX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:NLTX
DataOraFonteTitoloSimboloCompagnia
09/08/202422:15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NLTXNeoleukin Therapeutics Inc
09/08/202413:31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NLTXNeoleukin Therapeutics Inc
17/06/202420:37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NLTXNeoleukin Therapeutics Inc
26/04/202420:34Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:NLTXNeoleukin Therapeutics Inc
26/04/202420:33Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:NLTXNeoleukin Therapeutics Inc
26/04/202420:33Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:NLTXNeoleukin Therapeutics Inc
18/03/202421:04Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:NLTXNeoleukin Therapeutics Inc
07/03/202422:29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NLTXNeoleukin Therapeutics Inc
20/02/202422:16Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:NLTXNeoleukin Therapeutics Inc
15/02/202400:05Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:NLTXNeoleukin Therapeutics Inc
14/02/202422:26Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:NLTXNeoleukin Therapeutics Inc
19/01/202400:45Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:NLTXNeoleukin Therapeutics Inc
21/12/202322:05Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:NLTXNeoleukin Therapeutics Inc
15/12/202301:00GlobeNewswire Inc.Neoleukin Therapeutics Announces 1-for-4 Reverse Stock SplitNASDAQ:NLTXNeoleukin Therapeutics Inc
06/12/202322:24Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:NLTXNeoleukin Therapeutics Inc
14/11/202306:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:NLTXNeoleukin Therapeutics Inc
08/11/202320:34Edgar (US Regulatory)Form S-4/A - Registration of securities, business combinations: [Amend]NASDAQ:NLTXNeoleukin Therapeutics Inc
22/09/202314:00GlobeNewswire Inc.Neoleukin Therapeutics Announces 1-for-5 Reverse Stock SplitNASDAQ:NLTXNeoleukin Therapeutics Inc
18/07/202312:30GlobeNewswire Inc.Neurogene and Neoleukin Announce Definitive Merger AgreementNASDAQ:NLTXNeoleukin Therapeutics Inc
12/06/202322:04Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NLTXNeoleukin Therapeutics Inc
08/05/202322:19Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:NLTXNeoleukin Therapeutics Inc
27/04/202320:01Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:NLTXNeoleukin Therapeutics Inc
27/04/202318:48Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:NLTXNeoleukin Therapeutics Inc
27/04/202318:44Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:NLTXNeoleukin Therapeutics Inc
14/04/202322:52Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:NLTXNeoleukin Therapeutics Inc
21/03/202311:02Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:NLTXNeoleukin Therapeutics Inc
10/03/202314:20Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NLTXNeoleukin Therapeutics Inc
08/03/202323:00GlobeNewswire Inc.Neoleukin Therapeutics Provides Strategic Update and Announces Restructuring and Leadership TransitionNASDAQ:NLTXNeoleukin Therapeutics Inc
14/02/202322:40Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:NLTXNeoleukin Therapeutics Inc
03/02/202317:56Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:NLTXNeoleukin Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:NLTX

La tua Cronologia

TSXV
EMO
Emerita Resources
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network